2404 related articles for article (PubMed ID: 16377065)
1. Safety and efficacy of low dose hCG for luteal support after triggering ovulation with a GnRH agonist in cases of polyfollicular development.
Krause BT; Ohlinger R
Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):87-92. PubMed ID: 16377065
[TBL] [Abstract][Full Text] [Related]
2. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
[TBL] [Abstract][Full Text] [Related]
3. GnRH agonist as luteal phase support in assisted reproduction technique cycles: results of a pilot study.
Pirard C; Donnez J; Loumaye E
Hum Reprod; 2006 Jul; 21(7):1894-900. PubMed ID: 16556673
[TBL] [Abstract][Full Text] [Related]
4. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.
Babayof R; Margalioth EJ; Huleihel M; Amash A; Zylber-Haran E; Gal M; Brooks B; Mimoni T; Eldar-Geva T
Hum Reprod; 2006 May; 21(5):1260-5. PubMed ID: 16439507
[TBL] [Abstract][Full Text] [Related]
5. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
[TBL] [Abstract][Full Text] [Related]
6. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
Fatemi HM; Polyzos NP; van Vaerenbergh I; Bourgain C; Blockeel C; Alsbjerg B; Papanikolaou EG; Humaidan P
Fertil Steril; 2013 Sep; 100(3):742-7. PubMed ID: 23806846
[TBL] [Abstract][Full Text] [Related]
7. Endocrine modifications associated with final oocyte maturation with gonadotropin-releasing hormone agonists vs. human chorionic gonadotropin in women undergoing intrauterine insemination.
Díaz I; Guillén A; Pacheco A; Requena A; Garcia-Velasco JA
J Reprod Med; 2008 Jan; 53(1):33-9. PubMed ID: 18251359
[TBL] [Abstract][Full Text] [Related]
8. A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation.
Liang IT; Huang HY; Wu HM; Wang HS; Yu HT; Huang SY; Chang CL; Soong YK
Taiwan J Obstet Gynecol; 2015 Oct; 54(5):583-7. PubMed ID: 26522115
[TBL] [Abstract][Full Text] [Related]
9. [Onset and maintenance of the luteal phase with GnRH agonists or hCG in cycles under GnRH antagonists].
Olivennes F
J Gynecol Obstet Biol Reprod (Paris); 2004 Oct; 33(6 Pt 2):3S24-6. PubMed ID: 15643682
[TBL] [Abstract][Full Text] [Related]
10. Low-dose human chorionic gonadotropin versus estradiol/progesterone luteal phase support in gonadotropin-releasing hormone agonist-triggered assisted reproductive technique cycles: understanding a new approach.
Garcia-Velasco JA; Motta L; López A; Mayoral M; Cerrillo M; Pacheco A
Fertil Steril; 2010 Dec; 94(7):2820-3. PubMed ID: 20673892
[TBL] [Abstract][Full Text] [Related]
11. Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial.
Andersen CY; Elbaek HO; Alsbjerg B; Laursen RJ; Povlsen BB; Thomsen L; Humaidan P
Hum Reprod; 2015 Oct; 30(10):2387-95. PubMed ID: 26209535
[TBL] [Abstract][Full Text] [Related]
12. Steroid receptor expression in late follicular phase endometrium in GnRH antagonist IVF cycles is already altered, indicating initiation of early luteal phase transformation in the absence of secretory changes.
Papanikolaou EG; Bourgain C; Kolibianakis E; Tournaye H; Devroey P
Hum Reprod; 2005 Jun; 20(6):1541-7. PubMed ID: 15705618
[TBL] [Abstract][Full Text] [Related]
13. Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist- and antagonist-treated ovarian stimulation cycles.
Tesarik J; Hazout A; Mendoza-Tesarik R; Mendoza N; Mendoza C
Hum Reprod; 2006 Oct; 21(10):2572-9. PubMed ID: 16926261
[TBL] [Abstract][Full Text] [Related]
14. 1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study.
Humaidan P; Ejdrup Bredkjaer H; Westergaard LG; Yding Andersen C
Fertil Steril; 2010 Feb; 93(3):847-54. PubMed ID: 19200959
[TBL] [Abstract][Full Text] [Related]
15. GnRH agonist ovulation trigger and hCG-based, progesterone-free luteal support: a proof of concept study.
Kol S; Humaidan P; Itskovitz-Eldor J
Hum Reprod; 2011 Oct; 26(10):2874-7. PubMed ID: 21784738
[TBL] [Abstract][Full Text] [Related]
16. Hormonal characteristics of follicular fluid from women receiving either GnRH agonist or hCG for ovulation induction.
Andersen CY; Humaidan P; Ejdrup HB; Bungum L; Grøndahl ML; Westergaard LG
Hum Reprod; 2006 Aug; 21(8):2126-30. PubMed ID: 16682403
[TBL] [Abstract][Full Text] [Related]
17. [Peak follicular estradiol (E2) levels and midluteal progesterone/E2 ratios in ongoing pregnancies and nonconception cycles after ovulation induced with gonadotropins].
Ellenbogen A; David H; Libal Y; Ballas S
Harefuah; 1995 Dec; 129(11):455-6, 536. PubMed ID: 8846950
[TBL] [Abstract][Full Text] [Related]
18. Accelerated endometrial maturation in the luteal phase of cycles utilizing controlled ovarian hyperstimulation: impact of gonadotropin-releasing hormone agonists versus antagonists.
Saadat P; Boostanfar R; Slater CC; Tourgeman DE; Stanczyk FZ; Paulson RJ
Fertil Steril; 2004 Jul; 82(1):167-71. PubMed ID: 15237007
[TBL] [Abstract][Full Text] [Related]
19. HCG (1500IU) administration on day 3 after oocytes retrieval, following GnRH-agonist trigger for final follicular maturation, results in high sufficient mid luteal progesterone levels - a proof of concept.
Haas J; Kedem A; Machtinger R; Dar S; Hourvitz A; Yerushalmi G; Orvieto R
J Ovarian Res; 2014 Apr; 7():35. PubMed ID: 24694069
[TBL] [Abstract][Full Text] [Related]
20. GnRH agonist as novel luteal support: results of a randomized, parallel group, feasibility study using intranasal administration of buserelin.
Pirard C; Donnez J; Loumaye E
Hum Reprod; 2005 Jul; 20(7):1798-804. PubMed ID: 15890740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
